Presentation is loading. Please wait.

Presentation is loading. Please wait.

Late-Breaking Data on LDL-C Reduction

Similar presentations


Presentation on theme: "Late-Breaking Data on LDL-C Reduction"— Presentation transcript:

1 Late-Breaking Data on LDL-C Reduction

2 LDL Control in High-Risk Patients

3 Even in Clinical Studies Using High Intensity Therapy, Many Do Not Reach Goal

4 2019 ESC Dyslipidemia Guidelines

5 Goals of 2019 ESC Dyslipidemia Guidelines

6 Targeting PCSK9

7 FOURIER Trial Design

8 FOURIER: LDL-C

9 FOURIER Outcomes

10 ODYSSEY OUTCOMES: Study Design

11 ODYSSEY OUTCOMES: Primary Efficacy Endpoint

12 Safety

13 Effect of the Combined Measure of Adherence x Intensity on LDL-C Reduction

14 Effect of the Combined Measure of Adherence x Intensity on Cardiovascular Risk

15 Estimate of the Benefit from Optimal Adherence and Intensity on Cardiovascular Events

16 Challenge is to Achieve Chronic Sustained LDL Reductions LDL-C Variability Common, Associated With Worse Outcomes

17 Therapeutic Approaches to Reducing LDL-C via the LDL Receptor: Small Molecules, Mabs, siRNA

18 Inclisiran Efficacy: One Dose Starting Regimen Robust, Sustained LDL-C Reductions – 300 mg Optimal

19 Efficacy: Two Dose Starting Regimen Robust, Sustained LDL-C Reductions – Optimal Start Regimen

20 Efficacy: Two Dose Starting Regimen Individual Patient Responses (%) at Day 180

21 ORION-11

22 ORION-11: Study Design Eighteen Months Treatment and Observation

23 ORION-11: Patient Disposition High Proportion of Patients Completed 18-Month Study

24 ORION-11: Patients Representative High Risk Cohort Balanced by Randomization

25 ORION-11: Efficacy Highly Significant Lowering of LDL-C Relative to Placebo

26 ORION-11: Efficacy Durable, Potent, and Consistent Effect Over 18 Months

27 ORION-11: Safety and Tolerability Adverse Event Profile Similar to Placebo

28 ORION-11: Safety and Tolerability Injection Site AEs Localized, Mostly Mild and Transient

29 ORION-11: Safety and Tolerability No Evidence of Liver, Kidney, Muscle, or Platelet Toxicity

30 ORION-11: Safety and Tolerability No Difference in Serious Adverse Events

31 ORION-11: Exploratory Endpoint Adverse Cardiovascular Events

32 ORION-4 Design

33 Abbreviations


Download ppt "Late-Breaking Data on LDL-C Reduction"

Similar presentations


Ads by Google